Katarina Luptakova - 01 Jan 2025 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ Kevin Brennan, Attorney-in-Fact
Issuer symbol: XLO
Transactions as of: 01 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jan 2025, 16:15:26 UTC
Previous filing: 03 May 2024
Next filing: 25 Nov 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XLO	Common Stock	Options Exercise		+16,625			16,625	01 Jan 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XLO	Restricted Stock Units	Options Exercise	$0	-16,625	-25%	$0.000000	49,875	01 Jan 2025	Common Stock	16,625		Direct	F1, F2
transaction	XLO	Stock Option (right to buy)	Award	$0	+200,000		$0.000000	200,000	01 Jan 2025	Common Stock	200,000	$0.9550	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs) convert to stock on a one-for-one basis
F2	These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028.
F3	The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029.